Abstract:Background The determination of HER2 expression status contributes significantly to HER2-targeted therapy in breast carcinoma. However, an economical, efficient, and non-invasive assessment of HER2 is lacking. We aimed to develop a clinicoradiomic nomogram based on radiomics scores extracted from multiparametric MRI (mpMRI, including ADC-map, T2W1, DCE-T1WI) and clinical risk factors to assess HER2 status. Methods We retrospectively collected 214 patients with pathologically confirmed invasive ductal carcinoma between January 2018 to March 2021 from Fudan University Shanghai Cancer Center, and randomly divided this cohort into training set ( n = 128, 42 HER2-positive and 86 HER2-negative cases) and validation set ( n = 86, 28 HER2-positive and 58 HER2-negative cases) at a ratio of 6:4. The original and transformed pretherapy mpMRI images were treated by semi-automated segmentation and manual modification on the DeepWise scientific research platform v1.6 ( http://keyan.deepwise.com/ ), then radiomics feature extraction was implemented with PyRadiomics library. Recursive feature elimination (RFE) based on logistic regression (LR) and LASSO regression were adpoted to identify optimal features before modeling. LR, Linear Discriminant Analysis (LDA), support vector machine (SVM), random forest (RF), naive Bayesian (NB) and XGBoost (XGB) algorithms were used to construct the radiomics signatures. Independent clinical predictors were identified through univariate logistic analysis (age, tumor location, ki-67 index, histological grade, and lymph node metastasis). Then, the radiomics signature with the best diagnostic performance (Rad score) was further combined with significant clinical risk factors to develop a clinicoradiomic model (nomogram) using multivariate logistic regression. The discriminative power of the constructed models were evaluated by AUC, DeLong test, calibration curve, and decision curve analysis (DCA). Results 70 (32.71%) of the enrolled 214 cases were HER2-positive, while 144 (67.29%) were HER2-negative. Eleven best radiomics features were retained to develop 6 radiomcis classifiers in which RF classifier showed the highest AUC of 0.887 (95%CI: 0.827–0.947) in the training set and acheived the AUC of 0.840 (95%CI: 0.758–0.922) in the validation set. A nomogram that incorporated the Rad score with two selected clinical factors (Ki-67 index and histological grade) was constructed and yielded better discrimination compared with Rad score ( p = 0.374, Delong test), with an AUC of 0.945 (95%CI: 0.904–0.987) in the training set and 0.868 (95%CI: 0.789–0.948; p = 0.123) in the validation set. Moreover, calibration with the p -value of 0.732 using Hosmer–Lemeshow test demonstrated good agreement, and the DCA verified the benefits of the nomogram. Conclusion Post largescale validation, the clinicoradiomic nomogram may have the potential to be used as a non-invasive tool for determination of HER2 expression status in clinical HER2-targeted therapy prediction.

Noninvasive Imaging Signatures of HER2 and HR Using ADC in Invasive Breast Cancer: Repeatability, Reproducibility, and Association with Pathological Complete Response to Neoadjuvant Chemotherapy

Quantification of Intratumoral Heterogeneity Using Habitat-Based MRI Radiomics to Identify HER2-positive, -Low and -Zero Breast Cancers: a Multicenter Study

Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI

Artificial intelligence reveals features associated with breast cancer neoadjuvant chemotherapy responses from multi-stain histopathologic images

HER2 Immunohistochemistry Staining Positivity is Strongly Predictive of Tumor Response to Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer.

Radiomic Signatures Derived from Diffusion-Weighted Imaging for the Assessment of Breast Cancer Receptor Status and Molecular Subtypes

Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer

Identification of A 10-Gene Signature to Predict Efficacy of Neoadjuvant Therapy in Patients with HER2 Positive Breast Cancer.

Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer

MRI-based machine learning radiomics for prediction of HER2 expression status in breast invasive ductal carcinoma

Radiomic Analysis of DCE-MRI for Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.

Radiomics Analysis of Multi-Phase DCE-MRI in Predicting Tumor Response to Neoadjuvant Therapy in Breast Cancer

Predictive value of radiomic signature based on 2-[18F]FDG PET/CT in HER2 status determination for primary breast cancer with equivocal IHC results

Test–retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial

Dynamic Contrast-Enhanced Magnetic Resonance Imaging Features and Apparent Diffusion Coefficient Value of HER2-positive/HR-negative Breast Carcinoma.

Radiomics Features for Distinguishing True Recurrence Versus New Primary Tumor Following Breast-Conserving Treatment

Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis

CT-Based Peritumoral and Intratumoral Radiomics as Pretreatment Predictors of Atypical Responses to Immune Checkpoint Inhibitor Across Tumor Types: A Preliminary Multicenter Study

Development and validation of a clinicoradiomic nomogram to assess the HER2 status of patients with invasive ductal carcinoma

Computational Pathology Improves Risk Stratification of a Multi-Gene Assay for Early Stage ER+ Breast Cancer

Value of CT-Based Radiomics in Predicating the Efficacy of Anti-HER2 Therapy for Patients With Liver Metastases From Breast Cancer